Directors

The present invention relates to stable liquid oral pharmaceutical formulations of cannabidiol (CBD). The invention further discloses methods of producing a stabilized formulation of cannabidiol using cannabidiol from a synthetic source.

Solubilized Formulations Of Atorvastatin Calcium

Enclosed

Novel Omega 3 Carrier Preparations For Inhalation Drug Delivery For Treating Lung Inflammation

ABSTRACT Inflammatory disorders of the lung are induced by COVID-19 disease, asthma, and numerous other disorders. Omega-3 fatty acids (03FA ), particularly docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) or eicosapentaenoic acid (EPA), have known anti-inflammatory and pro-resolving properties. Redúction of...

Novel Parenteral Formulations Of Cannabidiol

Enclosed

Liquid Parenteral Formulations Of Bilastine Free Of Cyclodextrins

The present invention relates to liquid pharmaceutical formulations of bilastine and a process of preparing such formulations.these formulations are used to treat conditions caused by allergens or foreign substances.

Liquid Parenteral Formulations Of Bilastine

Stable Formulations Of Bilastine For Nasal And Ophthalmic Use

Enclosed

Cannabidiol Compositions For Anxiety Disorders

The present invention relates to pharmaceutical compositions of cannabidiol comprising less than 0.3% of THC for treating various anxiety disorders. The invention also discloses evaluation of efficacy, safety and pharmacokinetics of these compositions for treating mild to moderate anxiety disorders. ...

Documents

LLP Form18-17052021-signed

FiLLiP-17052021-signed

Certificate on conversion of private company/ unlisted public company into LLPP - 17MAY2021

LLP Form18-13052021

Copy of approval from the competent authority in case of collaboration and connection with the foreign country or place-13052021

Copy of acknowledgement of latest income tax return.-13052021

Copy of approval from Central Government as a proof of no objection-13052021

Detail of LLP(s) and/ or company(s) in which partner/ designated partner is a director/partner-13052021

FiLLiP-13052021

List of all the secured creditors along with their consent.-13052021

Optional Attachment-(1)-13052021

Optional Attachment-(2)-13052021

Optional Attachment-(3)-13052021

Optional Attachment-(4)-13052021

Optional Attachment-(5)-13052021

Proof of address of registered office of LLP-13052021

Statement of Assets and Liabilities of the company duly certified as true and correct by the auditor.-13052021

Statement of shareholders-13052021

Subscribers Sheet including consent-13052021

Where the appointed partner is a body corporate, copy of resolution on the letterhead and a copy of resolution/ authorization also on letterhead mentioning the name and address-13052021

Optional Attachment-(5)-10042021

Optional Attachment-(4)-10042021

Optional Attachment-(3)-10042021

Optional Attachment-(2)-10042021

Optional Attachment-(1)-10042021

List of all the secured creditors along with their consent.-10042021

Detail of LLP(s) and/ or company(s) in which partner/ designated partner is a director/partner-10042021

Copy of approval from the competent authority in case of collaboration and connection with the foreign country or place-10042021

Copy of approval from Central Government as a proof of no objection-10042021

Copy of acknowledgement of latest income tax return.-10042021

Company Information

Directors

Patents

Documents